Drugs / PVT401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07423000 | Apr 2026 → Nov 2027 expected | inflammatory bowel disease | Parvus Therapeutics, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-30 | Parvus Therapeutics, Inc. | Parvus Therapeutics Initiates First-in-Human Clinical Trial of PVT401 for Inflammatory Bowel Disease parvustx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PVT401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07423000 ↗ |
| Modality | Other / unclassified | “PVT401 is a nanomedicine” NCT07423000 ↗ |
| Route | Intravenous | “PVT401 will be administered intravenously to healthy volunteers” NCT07423000 ↗ |